OmniSeq News
Cancer-testis antigen detection by targeted RNA sequencing
Abstract Background: Cancer-testis antigens (CTAs) have restricted expression in normal adult tissues but have been found to be overexpressed in multiple tumors. This and their ability to elicit spontaneous cellular and humoral immune responses have rendered CTAs as...
Cancer testis antigen co-expression landscape in solid tumors
Abstract Background Cancer testis antigens (CTAs) are tumor antigens that have a highly tissue-restricted expression but are often expressed in diverse malignancies. With their highly immunogenic expression limited to tumor cells, CTAs have become a prime target for...
PD-L1 by RNA next generation sequencing: Comparison with PD-L1 IHC 22C3 and association with survival benefit from pembrolizumab with or without chemotherapy in non-small cell lung cancer
Yong Hee Lee, Grace Dy, Paul DePietro, Jeffrey Conroy, Sarabjot Pabla and Mary Nesline Abstract Background PD-L1 immunohistochemistry (IHC) testing is suboptimal for predicting patient clinical benefit for checkpoint inhibition, while PD-L1 liquid biopsy is not...
Complex markers of survival from pembrolizumab: the potential predictive role of tumor mutational burden (TMB) and KRAS
Yong Hee Lee, Carrie Hoefer, Paul DePietro and Mary Nesline Abstract Background Pembrolizumab, with or without chemotherapy, is NCCN guideline-recommended treatment for NSCLC cancer patients depending on tumor PD-L1 status by IHC. PD-L1 IHC provides guidance for...
OmniSeq Receives ISO Certification for Quality Management Systems
BUFFALO, N.Y., Dec. 1, 2020 /PRNewswire/ -- OmniSeq®, an innovator in next generation sequencing (NGS) in oncology, today announced the company has received the International Organization for Standards (ISO) 13485:2016 certification for its Quality Management Systems...
OmniSeq Offers Differentiating Platform to Clinically Detect Rare Genetic Alterations to Identify Patients Eligible for New, Targeted Therapy for Lung and Thyroid Cancer
NGS Test Uses RNA-Sequencing to Detect RET Fusions and DNA-Sequencing to Detect RET Mutations BUFFALO, N.Y., June 29, 2020 /PRNewswire/ -- OmniSeq®, an innovator in next generation sequencing (NGS) in oncology, today announced the benefits of its OmniSeq Advance®...
OmniSeq Appoints Chief Medical Officer, Roger D. Klein, M.D., J.D., FCAP
FOR IMMEDIATE RELEASE MEDIA CONTACT: Sawyer Lipari Lambert & Co. 313.309.9551 slipari@lambert.com OmniSeq Appoints Chief Medical Officer, Roger D. Klein, M.D., J.D., FCAP Leading molecular diagnostic company’s new hire to support oncology product development...
Roswell Park’s Dr. Pawel Kalinski to Lead $14.5M NCI-Funded Immunotherapy Effort
Roswell Park’s Dr. Pawel Kalinski to Lead $14.5M NCI-Funded Immunotherapy Effort
OmniSeq Names Dr. Shengle Zhang as New Lab Director
FOR IMMEDIATE RELEASE MEDIA CONTACT: Sawyer Lipari Lambert & Co. 313.309.9551 slipari@lambert.com OmniSeq Names Dr. Shengle Zhang as New Lab Director Fast-growing cancer diagnostic laboratory continues focus on development of innovative product breakthroughs...
